| Name | Title | Contact Details |
|---|---|---|
Kelley Boucher |
Chief People Officer | Profile |
Kelley Boucher |
EVP, Chief Human Resources Officer at Alnylam Pharmaceuticals | Profile |
Dahna Walsh |
Manager, People Operations | Profile |
Chris Brown |
Director GxP audits and supplier management | Profile |
Michele Ronis |
Regional Sales Director | Profile |
ProThera Biologics, LLC (Main) is a East Providence, RI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Halo Labs is all about particle analysis. We live to find particles, analyze them, count them, and help our customers characterize them to better their biopharmaceutical products.
Flagship Biosciences, Inc. is a technology-driven tissue analysis services company delivering the most accurate and informative data for improved drug development and diagnostics. The company offers a full range of tissue analysis services using its award-winning technology to deliver breakthrough contextual data supported by a team of experienced pathology and scientific experts. It caters to pharmaceutical, biotechnology, and clinical diagnostic companies. Flagship Biosciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
Ostioporsis Imaging Ctr/Breast is a Palm Harbor, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte`s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and the XpressCFᵀᴹ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company`s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte`s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.